The emergence of medications like copyright and Semaglutide signifies a significant shift in how we treat type 2 diabetes. These innovative therapies belong to a class known as GLP-1 action agonists, which duplicate the effects of a natural hormone that regulates glucose levels and appetite. Originally, developed for diabetes, their effectiveness i